Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 12/20 | 0.49 |
| ▸ | BCHE | P06276 | 4/20 | 0.44 |
| ▸ | ACHE | P22303 | 4/20 | 0.44 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10025534 | 0.96 | MAOB (0.45) | MAOBBCHEACHEPDE3BPDE3A | |
| SCHEMBL3497864 | 0.77 | HRH3 (0.44) | MAOBPDE3BPDE3A | |
| SCHEMBL13541777 | 0.76 | PDE3B (0.36) | PDE3BPDE3A | |
| SCHEMBL10025565 | 0.73 | UTS2R (0.50) | MAOBBCHEACHEUTS2R | |
| SCHEMBL6743257 | 0.72 | PPARG (0.32) | ACHEPDE3BPDE3A | |
| SCHEMBL10025536 | 0.71 | HRH3 (0.43) | ACHEPDE3BPDE3A | |
| SCHEMBL10025543 | 0.69 | TLR7 (0.34) | PDE3BPDE3A | |
| SCHEMBL10058198 | 0.65 | SLC6A2 (0.60) | MAOBBCHEACHESLC6A2SLC6A4 | |
| SCHEMBL13541823 | 0.64 | SLC6A2 (0.65) | MAOBBCHEACHESLC6A2SLC6A4 | |
| SCHEMBL10025523 | 0.64 | SLC6A2 (0.58) | MAOBBCHEACHESLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207173-B2 | Benzimidazoles and analogs thereof as antivirals | ISIS PHARMACEUTICALS, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-8207173-B2 | Benzimidazoles and analogs thereof as antivirals | ISIS PHARMACEUTICALS, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-20100130513-A1 | BENZIMIDAZOLES AND ANALOGS THEREOF AS ANTIVIRALS | ISIS PHARMACEUTICALS, INC. (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100130513-A1 | BENZIMIDAZOLES AND ANALOGS THEREOF AS ANTIVIRALS | ISIS PHARMACEUTICALS, INC. (US) | 2010-05-27 | — | — | US | disclosed |
| US-7642265-B2 | Benzimidazoles and analogs thereof as antivirals | ISIS PHARMACEUTICALS, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-7642265-B2 | Benzimidazoles and analogs thereof as antivirals | ISIS PHARMACEUTICALS, INC. (US) | 2010-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130513-A1 | BENZIMIDAZOLES AND ANALOGS THEREOF AS ANTIVIRALS | ZC3HAV1, NXF1, ZC3HAV1L | MAOB 1784/4885BCHE 4032/4885ACHE 3798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.